Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series
Nathalie Forgeard(Hôpital Saint-Louis), Bertrand Arnulf(Université Paris Cité), Alexander Carpinteiro(Essen University Hospital), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Lionel Karlin(Hôpital Lyon Sud), Laurent Pascal(Groupe Hospitalier de l'Institut Catholique de Lille), Vincent Javaugue(Université de Poitiers), Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Monique C. Minnema(University Medical Center Utrecht), Stefan Schönland(Heidelberg University), Dikélélé Elessa(Université Paris Cité), Alexis Talbot(Gladstone Institutes), Karim Belhadj(Hôpitaux Universitaires Henri-Mondor), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Ute Hegenbart(Heidelberg University), Romain Gounot(Assistance Publique – Hôpitaux de Paris), Frank Bridoux(Université de Poitiers), Stéphanie Harel(Hôpital Saint-Louis), Antoine Huart, Efstathios Kastritis(National and Kapodistrian University of Athens)
Cited by 52
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k